Unlimited Bio is pioneering a comprehensive platform that targets aging as a multi-system failure by integrating gene therapies, biologics, plasma interventions, cell therapies, and small molecules to address various biological mechanisms involved in aging.

Their initial gene therapies focus on VEGF-A and Follistatin for vascular and muscular health, along with α-Klotho and BDNF for cognitive and neuroprotective benefits, with VEGF-A showing notable success in peripheral ischemia treatments since 2011.

The company plans to begin a first-in-human study in late 2025 or early 2026, testing a combination of two gene therapies in healthy volunteers to assess safety and potential synergistic rejuvenation effects, pending regulatory approval.

Looking ahead, Unlimited Bio aims to expand its therapeutic combinations across molecular, cellular, and systemic levels, leveraging emerging longevity research to optimize interventions over the next decade.

Immortal Dragons, a Singapore-based longevity investment fund with $40 million dedicated to radical life-extension technologies, has made a strategic investment in Unlimited Bio.

This investment aligns with Immortal Dragons' focus on engineering-centric approaches to longevity, complementing its existing portfolio that includes biofabrication and artificial womb technology, and broadening its scope into therapies that enhance healthy lifespan.